The Claim Died. Now What?

Every conversation about denied claims naturally focuses on the money. The write-off is certainly real: a $26,000 drug purchased on credit, administered to the patient, denied by the payer and written off to bad debt. That is not an abstraction. That is cash the practice will never recover, sitting on a distributor’s invoice that is still due in 15 days.

But the write-off is not where the damage stops. It is where the damage starts. After the claim dies, the practice changes how it operates, and the decisions that follow are invisible to everyone outside the building.

I have spent the last few years reading payer correspondence files across independent oncology, hematology, rheumatology, neurology, GI, ophthalmology and infusion practices in multiple states. Every file contains the same claim lifecycle: authorization approved, drug purchased on credit, drug administered, claim denied, appeal filed, appeal upheld, claim written off. That sequence is well understood by anyone in specialty billing. What is not well understood is what happens after step seven.

The practice absorbs the loss, and then adjusts

When a practice writes off a denied claim on a high-cost drug, it does not simply lose money and keep operating the same way. The write-off is a financial signal that feeds directly into clinical and operational decisions. Here is what I have actually seen happen. Not in theory. In the files.

Drug protocol substitution

An ambulatory surgery center in Texas was giving a brand antiemetic before cataract procedures to prevent severe post-surgical nausea. The payer rolled the drug line into the facility fee and paid nothing on the drug. The ASC appealed on clinical grounds, arguing medical necessity. The payer upheld the denial, because the appeal argued clinical need and the denial was about how the payer’s system classified the payment, not whether the drug was necessary.

The ASC wrote off the claim, then removed the drug from its pre-operative kits entirely. Not because the drug was unnecessary, but because the facility could not absorb repeated zero-dollar reimbursements on a drug it bought at full acquisition cost. Patients who had cataract surgery there afterward received a different nausea protocol. Not because the clinical evidence changed. Because the reimbursement changed.

An ASC in California had the same thing happen with a non-opioid pain management drug given during total knee arthroplasty. The payer rolled the drug into the primary surgical payment. The appeal included the orthopedic surgeon’s letter on avoiding heavy post-operative opioids. The payer agreed the pain management was necessary and upheld the denial anyway, because a clinical letter cannot overwrite a hard-coded payment indicator in an automated claims system.

The ASC took the loss and used less of the drug on later cases. Patients received more opioids after surgery because the non-opioid alternative stopped getting reimbursed. Nobody made a clinical decision that opioids were better. The claims system made a financial decision that the non-opioid drug was packaged.

Ordering behavior changes

This one runs across every specialty practice I have reviewed. When a practice gets hit with repeated denials on a specific drug from a specific payer, it stops ordering that drug for patients on that payer. Not formally, and not as a policy decision. It happens gradually, at the operational level.

The billing team flags the drug and payer combination as high denial risk. Prior authorization staff start steering patients toward alternatives with cleaner claims histories with that payer. The physician may not even know the substitution is happening, because it is framed as a prior authorization issue: we’re having trouble getting this one approved through UHC, the alternative is going through without resistance, do you want to switch? The physician switches. Not because the clinical evidence supports it. Because the claims environment made it necessary.

I have seen this on Keytruda. On Enhertu. On biosimilar transitions where the reference biologic pays and the biosimilar gets CO-96 denials from fee schedule lag. The practice goes back to the reference biologic, the biosimilar transition stalls, and the manufacturer sees a volume decline with no idea it was caused by a fee schedule synchronization failure at the payer.

Patient access restrictions

Multi-site infusion centers and alternate-site operators are the most exposed. When a payer’s authorization system stores NPI and location data differently from its claims system, every claim from a satellite location risks an NPI routing mismatch. The authorization was issued under the primary NPI; the claim was submitted under the satellite NPI. The payer’s own systems created the mismatch, and the denial says no authorization on file.

After enough of these denials, the practice stops scheduling certain drugs at certain locations. High-cost biologics get consolidated at the primary site, where the NPI routing is clean. Satellite locations lose volume, and patients who were treated closer to home are told to drive across town for their next infusion. Access narrows. Not because of a clinical decision. Because of a claims routing failure.

For home infusion patients it is worse. The home infusion dispatch modifier creates its own NPI mismatch against the authorizing facility’s NPI. The claim denies, and the practice stops offering home infusion for that drug on that payer. The patient comes into the clinic or doesn’t get treated. The payer never decided home infusion wasn’t covered. Its claims system just couldn’t reconcile the NPI.

The maintenance patient abandonment

This is the one that gets to me. Chronic patients on long-term biologic maintenance: infliximab every eight weeks for two years, Ocrevus every six months, IVIG every three weeks. The patient is stable, the drug is working, and the authorization has been renewed several times without issue.

Then the payer’s system reapplies a step therapy requirement, mid-regimen, on a patient who already cleared step therapy when treatment started. No clinical change. No new medical policy. No physician review. Just an automated response on a high-cost maintenance biologic.

The claim denies. The billing team has no clear pathway, because the standard appeal process addresses new step therapy determinations, not retroactive reinstatement on established regimens. The appeal fails, and the claim is written off.

Now the practice has a patient who needs their next infusion in three weeks, and the last claim didn’t pay. The drug costs thousands of dollars, distributor credit terms are 15 to 30 days, and the appeal clock is running. The math doesn’t work. Some practices keep treating and eat the risk. Some delay the next infusion until the appeal resolves. Some tell the patient to switch to a drug that is going through clean on that payer right now. Either way, the patient’s treatment is interrupted or changed, because an automated system reapplied a barrier it had already cleared.

What to do with this

If you run a specialty practice, an infusion center or an ASC and you’ve written off denied claims on high-cost drugs in the last 12 months, look at what changed operationally after those write-offs. Did you pull a drug from a protocol? Stop scheduling certain drugs at certain locations? Switch patients to alternatives because the original drug kept getting denied by a specific payer? Delay or interrupt a maintenance regimen because the claim didn’t pay?

If any of that happened, go back to the denied claims that triggered it. Pull the full correspondence record: the authorization, the EOB, the appeal, the uphold. Read them against each other. In most cases you’ll find the denial was a system error formatted as a coverage denial, and the change you made was a rational response to a false signal.

The claims are recoverable. The change doesn’t have to be permanent. But only if someone reads the file correctly before the timely filing window closes.